Mapping the effectiveness and risks of GLP-1 receptor agonists
An erratum to this article was published (Nat Med, Mar 2025 ↗)
Authors' conclusion
The results provide insights into the benefits and risks of GLP-1RAs
Study context
- Population
- People with diabetes, US Department of Veterans Affairs databases175 outcomes mapped
- Exposure
- GLP-1RA initiation vs SU, DPP-4i, SGLT2i, a composite control or usual care
- Outcome
- Associations of GLP-1RA use vs each comparator with 175 health outcomes
Methodological detailsdiscovery approach, US Department of Veterans Affairs databases, multiple active and usual-care comparators
- Discovery approach
- US Department of Veterans Affairs databases
- Multiple active and usual-care comparators
Main finding
As reported in the abstract
Health outcomes, GLP-1RA vs usual care
- Reduced risk with GLP-1RA vs usual care: substance use and psychotic disorders, seizures, neurocognitive disorders (incl. Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions
Observational data: associations, not effects.
Safety
- Increased risk of GI disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis with GLP-1RA vs usual care
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat Med. Published 20 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →